Respirable nanocarriers as a promising strategy for antitubercular drug delivery

The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity

“…1 According to the World Health Organization reports, TB together with the acquired immunodeficiency syndrome and malaria are the most fatal diseases worldwide; therefore, better management must be assessed. 1 The current TB therapy possesses many obstacles as the oral drug administration requires a prolonged time over 6-9 months resulting in a poor patient compliance. 2 For decades, TB is treated by first-line anti-TB drugs regimen, which include isoniazid, rifampicin (RIF), pyrazinamide, and ethambutol.…”

“…Treatment of such cases is much more difficult; the therapy is based on second-line agents that include amino glycoside antibiotics, cycloserine, ethionamide, and fluoroquinolones. 1,2 Conversely, these agents are more…”

Pulmonary drug delivery systems for tuberculosis treatment

“…In the last case the drug-loaded particles plays the role of the Table 2 Structures, minimum inhibitory concentration and mechanism of action of anti-TB drugs. For doses and routes of administration see Table 1 of (Mehanna et al, 2014).…”

“…Besides the advances obtained using microparticles, researchers also have considered nanoparticles for antitubercular inhaled therapy (Table 5) as reviewed previously (Andrade et al, 2013;Mehanna et al, 2014). Inhalable nanoparticles can achieve a high drug loading , a better mucosal cell adherence, hence, enhancing net drug delivery to the lungs (Pandey and Khuller, 2005a).…”

Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation

“…There are many reports emphasizing the need for inhalation formulation for treating tuberculosis (TB) [28]. The widely accepted mode of TB treatment is prolonged intake of fixed dose combination (FDC) tablet containing rifampicin, isoniazid, ethambutol and pyrazinamide.…”